SecBot SecBot
6-K ·Filed May 7, 2026

DRTSW

Alpha Tau Medical Ltd.
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001213900-26-053086
Notable filing: 6-K
Actionable Insight • Neutral

Early clinical milestone unlikely to move shares near term; focus on interim safety data after first 5 patients for potential catalyst. Historical stock reaction to similar updates has been weak.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 7, 2026 · via day close
Latest settled
+152.94%
T+60 · $2.58
Vs SPY
+149.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $1.02entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $1.02
  3. T+5 · 6mo ago 0.00%α −1.50% · $1.02
  4. T+20 · 6mo ago 0.00%α −3.14% · $1.02
  5. T+60 · 4mo ago +152.94%α +149.11% · $2.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau announced the first patient treated in Italy with its Alpha DaRT therapy for pancreatic cancer, a feasibility and safety study at the University of Verona's Pancreas Institute. The milestone expands the company's global pancreatic cancer program but represents an early-stage clinical update with no near-term revenue implications.

Key Facts

  • First Alpha DaRT pancreatic cancer patient treated in Italy under protocol CTP-PANC-03
  • Study plans to enroll up to 15 patients with locally advanced pancreatic cancer at a single center
  • First Alpha DaRT pancreatic protocol to permit both endoscopic ultrasound (EUS) and percutaneous delivery
  • Follows first European patient treated in April 2026 in France's ACAPELLA trial and ongoing U.S. IMPACT trial

Financial Impact

No financial data provided; zero-revenue clinical-stage company with no near-term commercialization impact

revenuecash burn rate

Risk Factors

  • Pancreatic cancer trials have high failure rate; feasibility/safety data may not translate to efficacy
  • Company has significant operating losses and requires additional funding; dilution risk

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-053086
Document: ea0289554-6k_alphatau.htm0001213900-26-053086
Document: 0001213900-26-053086-index-headers.html0001213900-26-053086
Document: 0001213900-26-053086-index.html0001213900-26-053086
Document: 0001213900-26-053086.txt0001213900-26-053086

Track record

14 reports on DRTSW

Performance horizon

9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Viewing Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026